Eisai Licenses Kissei’s Glufast For Southeast Asian Market
This article was originally published in The Pink Sheet Daily
Transaction dovetails with Eisai’s established marketing infrastructure for diabetes treatments, firm says.
You may also be interested in...
Silodosin would take on GSK’s Avodart and Pfizer’s Cardura XL.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee
Agency comes to same conclusion as advisory committee: the risky schizophrenia drug could get approved if an appropriate patient group is identified.